Ladies and gentlemen, thank you for standing by, and welcome to the Q3 Results 2019 Conference Call. At this time, all participants are in a listen only mode. There will be a presentation followed by a question and answer session. I also must advise you that this conference is being And I would now like to hand the conference over to your first speaker today, Mr. Jonathan Kurten.
Thank you. Please go ahead, sir.
Thanks, John. Good day, ladies and gentlemen. Thank you for joining us on this call covering the quarter ended September 30, 2019.
Also on the
call today, we have our CEO, Doctor. Steve Cutler and our CFO, Mr. Brendan Brennan. I would like to note that this call is webcast and that there are slides available to download on our website to accompany today's call. Certain statements in today's call will be forward looking statements.
Actual results may differ materially from those stated or implied by forward looking statements due to risks and uncertainties associated with the company's business and listeners are cautioned that forward looking statements are not guarantees of future performance. The company's filings with the Securities and Exchange Commission discuss the risks and uncertainties associated with the company's business. This presentation includes selected non GAAP financial measures. For a presentation of the most directly comparable GAAP financial measures, please refer to the press release statement headed Condensed Consolidated Statements of Operations U. S.
GAAP Unaudited. While non GAAP financial measures are not superior to or substitute for the comparable GAAP measures, we believe certain non GAAP information is more useful to investors for historical comparison purposes. From January 1, 2018, the revenue recognition standard ASC 606 became effective for
comprise both direct fee and pass through components. This
is comprised both direct fee and pass through components. This is consistent with financial measurement presented in quarter 1 and quarter 2 of this year. We will be limiting the call today to 1 hour and would therefore ask participants to keep their questions to 1 each with an opportunity to ask one related follow-up question. I would now like to hand over the call to our CFO, Mr. Brendan Brennan.
Thank you, Jonathan. In quarter 3, we achieved gross business wins of $1,079,000,000 We recorded 148 $1,000,000 word of cancellations. Consequently, net awards in the quarter were $931,000,000 resulting in a strong net book to bill of 1.31. On a trailing 12 month basis, our net book to bill was 1.32. With the addition of these new awards, our backlog grew to $8,400,000,000 This represents a year on year increase of 12%.
Revenue in quarter 3 was $710,400,000 This represents year on year growth of 8.5% or 9.5% on a constant currency basis. On a constant dollar organic basis, year on year revenue growth was 8.4%. Year to date revenue in quarter 3 was $2,080,000,000 This represents year on year growth of 8.5% or 10.3% on a constant currency basis. On a constant dollar organic basis, year on year revenue growth was 9.4%. Our top customer represented 11.4 percent of revenue for the quarter compared with 14.1% in quarter 3 2018.
We expect revenue concentration from our top customer to remain in line with our previously stated guidance of 11% to 13% of revenue for the full year. Growth outside our top customer on a trailing 12 month basis remained robust. Our top 5 customers represented 36.2% compared to 40.5% last year. Our top 10 represented 49.1% compared to 55% last year, while our top 25 represented 67.9% compared to 71.2% last year. Gross margin for the quarter was 29.7% compared to 29.4% in quarter 2 and 29.9% in comparable quarter last year.
As revenue growth continues, we continue to leverage our global business support model. As a result, SG and A was 12% of revenue in the quarter. This compared to 12% last quarter and 12.3% in the comparable period last year. Operating income for the quarter was $110,000,000 a margin of 15.5%. This compared to 15.3% last quarter and 15% in the comparable quarter last year.
The net interest expense for the quarter was $1,500,000 and the effective tax rate was 12%. Net income attributable to the group for the quarter was $94,800,000 a margin of 13.3 percent equating to diluted earnings per share of $1.74 This compares to earnings per share of $1.69 in quarter 2 and $1.54 in the comparable quarter last year, an increase of 13%. On a comparative non GAAP basis, days sales outstanding were 56 days at September 30, 2019. This compares with 61 days at the end of June 2019. The primary reason for our improvement this quarter can be attributed to the conversion of billed receivables into cash.
During the quarter, cash generated from operating activities was a strong $160,700,000 We remain focused on all elements of our DSO, particularly the transition of unbilled revenue to build debt. And we feel confident that our full year cash from operations will be in the range of $320,000,000 to $360,000,000 As you will have seen from the press release last night, during the quarter, the group completed the acquisition of Symphony Clinical Research. This was for an initial payment of $31,600,000 In addition, during the quarter, capital expenditure was $13,700,000 76,500,000 dollars worth of stock was repurchased at an average price of $151.80 At September 30, 2019, the company had net cash of $121,700,000 compared to net cash of $81,800,000 at June 30, 2019, and net cash of $142,300,000 at September 30, 2018. With all of that said, I'd now like to hand the call over to Steve.
Thank you, Brenda, and good morning, everyone. Quarter 3 was another quarter of excellent progress for ICON. During the quarter, we delivered record growth and net business wins, leading to a very healthy quarterly book to bill of 1.31 or 1.32 on a trailing 12 month basis. ICON's continuing positive business development performance means we grew our backlog by 12% year on year to nearly $8,400,000,000 and recorded a robust revenue increase year over year of 9.5 percent on a constant currency basis. As with recent prior periods, we continue to expand relationships and revenues from customers outside our top ten, which grew by over 20% on an annual basis.
As we develop these new customers, we expect to see further revenue growth from them as we move into 2020. We believe this diversification leaves us well positioned for consistent and sustainable future growth. The backdrop of a strong outsourcing landscape and continued biotech demand offers possibilities to broaden our existing customer base, and we are pleased to see new strategic alliance opportunities opening up across our clinical research, functional solutions and laboratory service lines. These customers are looking to leverage ICON's operational excellence, flexible partnership model and depth of therapeutic expertise across our global footprint, all underpinned by our differentiated patient, site and data strategy. In anticipation of our operational delivery requirements, significant proportion of our 2019 headcount hiring occurred during the earlier months of this year.
This meant that during quarter 3, we were able to improve utilization and expand our gross margin to 29.7% of revenue. Moving forward, we will continue to closely assess our hiring requirements in line with our project pipelines and will ramp our recruitment accordingly in line with project needs. As we balance revenue growth with our requirements for additional project resources, we continue to leverage our global business support model. During the quarter, we saw further evidence of this with SG and A remaining in line with the prior quarter at 12% of revenue, down from 12.3% last year. As we have demonstrated over the years, our SG and A leverage remains a key industry leading strength.
We have developed a strong positive culture within our support structure that is focused on best in class service delivery and appropriate cost saving initiatives. As we move forward into 2020 beyond, we will continue to balance our investment needs with savings opportunities in these areas. This continued focus on operational excellence and the proactive management of our cost base resulted in an operating margin of 15.5%, up from 15% last year. This led to an EPS increase of 13% year over year to $1.74 We continue to develop our patient, site and data strategy. At this time, I'm delighted to announce the acquisition of Symphony Clinical Research, a provider of site and patient clinical trial support services.
This acquisition concluded in late September, further enhances our ability to help solve our customers' key challenge of getting patients into clinical trials faster and more efficiently. The acquisition of Symphony complement ICON's existing PMG and MediNova site networks in the U. S. And Europe. Importantly, it means ICON can now offer patients at home trial services, which will make it more convenient and accessible for patients to participate in clinical trials.
This patient centric approach helps reduce the travel burden for patients broadening ICON's recruitable population and providing patients access to clinical research studies in which they may not have otherwise been able to participate. At home trial services will improve our ability to recruit and retain patients in traditional studies and crucially, it will also enhance our ability to conduct virtual trials as we move forward. Innovation the ability to execute effectively this emerging area will be a key differentiator in the future. In quarter 3, we repurchased $76,500,000 worth of shares at an average price of $151.80 This means in total, we have spent just under $141,600,000 year to date repurchasing 1,000,000 shares at an average price of $141.57 During the quarter, we also generated strong cash collections, helping us to achieve cash from operating activities of $161,000,000 This helped drive our DSO down to 56 days from 61 days last quarter. While the industry trends of customers looking for fewer billing milestones and elongated credit terms remain, we are committed to working with our partners to proactively improve our cash conversion cycle and lower this metric further over the medium term.
As we look forward with optimism on the business environment and confidence in our ability to continue to execute our strategy, want to take this opportunity to update our full year guidance. We expect 2019 revenue to increase to a range of $2,790,000,000 to $2,830,000,000 an increase of 7.5% to 9% year over year. And earnings per share to increase to a range of $6.81 to 6.95 dollars an increase of 11.8 percent to 14.1 percent year over year. Before moving to Q and A, I would like to welcome all the Symphony staff to ICON. And of course, thank the entire ICON team for all their hard work and commitment during the quarter.
Thanks everyone and
we're now ready for questions.
Thank you.
Thanks, guys. Good morning. Congrats on a good quarter. I just had a question. How should we think about the acquisition contribution from Symphony going forward?
Hi, forward?
Hi, Elizabeth, and welcome back to the Analyst Group. This is very much a strategic acquisition. So it will be relatively small in terms of quarterly contribution. And so really, you're really only looking at a couple of $1,000,000 on a quarterly basis. So we do see it as very, very important from a strategic perspective and obviously being there to really augment the patient experience, but it is relatively small in absolute terms.
Okay, perfect. And then one sort of more broader question. Have you could you comment a little bit on the any changes in perhaps like site network competition in the quarter or any sort of changes in your offerings and the future margin opportunity there?
From a site network point of view, Elizabeth?
Yes.
No real changes. We're bringing the PMG and the MediNova site network together and then we'll overlay that with the services that Symphony offer us from a patient point of view. So that whole patient and site network is coming together. We're in the process of doing that. We're starting to see some good traction in terms of the increase in the proportion of patients recruited, the numbers of patients recruited into our trials, but there's no particular changes in terms of cost base at this point.
We anticipate we'll get some efficiencies as we complete those integrations. That's certainly the aim. But really it's around how we get patients into trials faster. That's the focus of that group.
That makes sense. Thank you very much.
Thank you. And we'll now take our next question and this comes from the line of John Kreger. Your line is now open. Please go ahead.
Hi, thanks. Good morning. This is John Kaufman on for Kreger. I realized that you haven't completed budgeting for 2020 yet, but do you have any broader observations on how you're thinking about next year?
I think it's John. No, we're looking at our business. We're actually just starting to go into our budgeting season. So we're going out to our business, looking at the markets, getting some input from various Okay
Okay. And then if you look across all of your client segments, are you seeing any signs of caution? And if so, is that coming from large pharma, midsized clients or perhaps the smaller biotech cohort?
We've seen I mean demand for our services across all of those segments continues to be very solid. Certainly, in the biotech space, we look at our year to date trailing 12 month numbers. The dollars are there. The dollars are up on a sort of mid single digit basis. So we feel good about that market.
I recognize that as we look at the same data as you from a funding point of view and probably the growth there has come off a little bit from where it was perhaps a couple of quarters or a year ago and we see that. But in terms of the opportunities we're seeing in that segment over a period of a year or so, we continue to see opportunity. We continue to see growth. Certainly, our backlog has benefited from that.
Okay, great. Thank you.
Thank you. And we will now take our next question and this comes from the line of Tito Peterson. Your line is now open. Please go ahead.
Hey, thanks. Wondering if you can talk to the DSO improvement. In the past, I think you've talked about longer times and extended credit terms. So can you maybe just talk to some of the drivers of the improvement in DSOs and how sustainable you think that trend is?
Tycho, it's Brendan here. Yes, no, it was good, very good quarter in terms of improvements. We would say we still have a lot of work to do and a lot of focus to put on there. I think we were particularly, as I mentioned in my prepared remarks, good at getting cash in on bills that are out the door in the current quarter. So it was very much focused on making sure that were collecting it as efficiently as we could, and that's where a lot of the improvement came from.
As we've spoken about in the past, those commercial pressures are still there around folks looking for fewer milestones and milestones being pushed out further into the contract. And that is something that is still a pressure point as we look at our DSO and the makeup of our balance sheet. But as we said, it is something that we're very focused on. It is something that we're working with our customers on particularly to ensure that we are seeing a good level of traction and pull through of our cash conversion cycle. But that said, it was a good quarter.
We are very happy, as I said, dollars 161,000,000 of cash from operations this quarter It gives us a very, very good cash conversion ratio of nearly 90% year to date on net income. So good pull through from that perspective, but still work to be done, particularly on that unbilled debt side.
Okay. And then one more for you, Brennan, before I hop over to Steve. Just plans for further share repos now that you've hit kind of the target for the year? Yes, Tycho, we'll keep our eyes to
the market. It's been a funny trading patterns over the last little while. I think opportunistically, we'll still look at the market in the 4th quarter. And if the opportunity presents itself, we will go beyond the 1,000,000 shares already done by the end Q3 and get back in the marketplace if the needle rises.
Okay. And then Steve, we've seen a little bit of resurgence on the Alzheimer's front here with the Biogen news. Can you just talk a little bit about your pipeline and CNS more broadly, how robust that is?
Yes, Taco, I'm not trying to get too carried away with aducanumab coming back into the submission stakes. I think there's certainly still some challenges there with regard to that. So I'm not going to get too carried away about the resurgence in the Alzheimer's market based on one sort of resubmission. However, if I look at our CNS portfolio, it continues to grow. It's in the neurology space and psychiatry space, it's an area we're continuing to invest in, in terms of bringing in new medical experts and project managers.
We feel we have a good network of sites that can do these sorts of trials. A number of the sites that we have in our network are also skilled in the CNS area. So we feel we're well placed to be able to benefit from any uptick in Alzheimer's trials or any other sort of neurological conditions or psychiatric conditions as they come through. It's a I think a strength of ours and one that we're looking to bring forward.
Okay. Thank you. Thanks, Doug.
Thank you. And your next question comes from the line of Robert Jones. Your line is now open. Please go ahead.
Hey, great. Thanks for the question. I guess, Steve, just to go back to where maybe some of the growth or what you're seeing in the different cohorts on the demand side. Clearly, bookings very strong in the quarter as you guys highlighted. Cancellations, I know you guys characterized as normal.
But I mean, maybe just to parse those out a bit, did you see anything, in particular from the smaller biotech cohort that either A, drove the incremental booking strength in the quarter or maybe had a disproportional contribution to the cancellation side of the equation?
Yes. Hi, Robert. No, it was I mean, certainly the growth as we mentioned outside our top 10 is very strong, very substantial. But sometimes you kind of naturally think that outside of our top ten customers, they typically are biotech customers. That's actually not the case.
So the growth we drove in that cohort, that outside top 10 was across the spectrum. Certainly, there were some smaller customers in there, but there were also some large and midsize customers in there as well. And that's what I was particularly pleased about. It's not 1 or 2 of the partnerships that we've been able to win over the last year, 18 months or so. Up the lead table, so to speak.
So we've got a I think we've got growth across the segments in that space. They were all biotechs, although of course the biotech business has grown reasonably substantially within our portfolio over the last really over the last couple of years, I suppose, 18 months or so. Certainly, they're a larger part of our backlog now than they were a year ago, although still very much a minority at around 20%, 25% of our backlog. So the growth, what I was pleased about was the growth was fairly broad based across the segments of our customer segments. And that was I think that's good for us.
It certainly gives us plenty of optimism in the future in terms of establishing or continuing to develop the relationship with companies who have a portfolio and have a budget that is not just around 1 or 2 projects, but around something much more sustainable.
Maybe just to add to that quickly, Bob, I think specifically on your point around cancellations in the quarter, don't think we really saw a skew towards a small biotech or large. It was pretty normal mix. Some of the reasons were for operational pieces, some for non. So there was nothing there, I think, from a therapeutic or a company size perspective that would indicate anything specific.
No, that's helpful. Good to hear. I guess just on I know you guys are not in a position yet as you mentioned to give specifics around 2020, but just so I can think about the way things have trended so far this year, it looks like you're pointing about somewhere north of 8% top line growth this year. You're on pace to grow the backlog in a similar range to what we saw last year. Is there anything unique or different about the type of wins or the progression of the type of wins that you've seen this year that we should think about as we look forward as far as it relates to conversion from backlog?
I think broadly speaking, no, Bob, the portfolio that we've won, as I said, it's been over the last 12, 24 months, there's been, I think, a larger proportion of biotech work in there. But we have, I think, a good spread of work right across the segments. Large pharma remain a core foundation of our backlog. That will continue. Midsize pharma is very strongly represented as is biotech.
So there's been nothing I think in the win profile over the last quarter or 2 that's going to mean we'll drive a different sort of profile as we get into 2020 beyond.
Great. Thanks so much.
Thank you. And your next question comes from the line of Juan Vendano. Your line is now open. Please go ahead.
Hi. Thank you. Regarding the point on the cancellations, I mean, I'm calculating a 1.8% cancellation rate in the quarter, which is at really low on historical terms. Am I looking at it correctly?
That's of opening backlog, Juan. Yes, no, that sounds like it's around the right percentage.
Okay. Low teens, I think it was growth. Yes. Yes, I think it was around our expectation. I don't think it was about average in Q1.
Yes, that was fair.
Okay, got it. No, just wanted to clarify that. And so cancellations are actually historically low. I guess staying on the backlog, could you share with us what your gross win growth rate on a reported basis was year over year in 3rd quarter and what it's been year to date?
Yes. The gross wins were in the low double digit range from a growth point of view, Juan. We were happy enough with that. It was a little higher on a net basis, but we go back to some comparisons that we didn't provide that further comparison back then. So we were happy with the sort of low double digits on a gross basis.
Good. All right. Thank you. And then have you noticed any changes at all in recent months in the pace of bookings from Bristol Myers Squibb?
We don't comment on specific bookings from specific customers. I'm not going to talk about any specific customer. We've seen continued progress across our large pharma card drive customers. It is a matter of public record that we're a supplier to Bristol Myers. We continue to have a good relationship with them.
We continue to work hard with them and that relationship is ongoing. So but I'm not going to comment on specific customers and specific bookings.
All right. Okay. Thank you. And lastly, if I may, can you give us an update on the percentage of patients that you're recruiting within your integrated site network in the quarter?
Yes. We certainly increased that on a year on year basis. It's up around 30% from last year. So we're happy to see the increase. It did come down a little bit in terms of the proportion of patients recruited.
That was partly because there were more there were fewer vaccine studies in this quarter. So it came down a little bit to close to around the 20%, 25%, but on a year to year basis, it's gone up. So we're continuing to see traction in that. And I think with Symphony coming on board, we'll get more traction around that because these guys, simply folks, will be helping to support and helping to expand that integrated SMO network. So I'm really pleased to see those 3 companies.
I said those 3 acquisitions come together with our site patient recruitment group to really solidify that offering and really make that a key part of what we do.
All right. Thank you.
Thank you. And your next question comes from the line of Dan Brennan. Your line is now open. Please go ahead.
Great. Thanks for the questions. I wanted to start off with strategic alliances. I think it was mentioned during the prepared remarks, you see some new opportunities. Maybe could you just elaborate a bit outside of your top client?
How much of your business today is made up of what you would consider to be strategic alliances? And any line of sight on these new opportunities which you mentioned?
Sure. We're not going to I mean, we're not going to comment on specific negotiations, Dan, that we're having at the moment. But I've been delighted with the opportunity that things like the MediNova acquisition have allowed us, have got us into some discussions with some large pharma potential strategic alliance customers on the lab front. So we continue to have those discussions and we're ongoing. And as we all know, these things take some time to come to fruition and certainly take some time before revenue starts to flow and wind starts to.
So we're still in the discussion negotiation phase. But we have good reason to believe that we are very well positioned on the lab front. Our functional services group, we're also in discussion with a couple of large very large providers of large alliance partners, one of which would be a very much a new customer to us. So we're very optimistic about that. But again, I don't want get too far ahead of myself on that front.
And then the ICR, our Phase II, Phase III business has also been able to make some progress in that area. And again, I think we see some opportunity there. So with these strategic alliances, I would say, revenue that we do in that sort of vicinity. I'd like it to be a little higher than that. We certainly see some opportunity to be for that to be a bit higher going forward.
It might be up to 30%, 30%, I think, as we go forward. So it's not a figure I'm actually holding my head. And so I'm sort of thinking a little bit off the top of my head here. But I think it's around about the 30%, 25% to 30 percent mark, maybe a third. And we see some opportunity, I think, to move that upwards.
And that's certainly what we're looking to do as we go forward.
Great, great. Thank you for that. I wanted just a second question on kind of your customer breakdown and understanding that customers move in and out of the buckets that you kind of define when you release. But nonetheless, I think clients numbers 2 through 5, I think those were growing nearly 30% the last 2 years and year to date, I think they're up low single digits. So anything specific to call out there?
I know you're not going to mention the customer, but just trying to understand that bucket which looks like it was a meaningful driver in the past.
Yes. I think on that one, we're slightly up in terms of the last quarter or so. But these things, as you said, they tend to go wax and wine a little bit. Customers jump in and out of them. I think where we've seen most of the progress is on the, as I say, beyond our top 10, which is really where I want to see most of the progress because we're moving some of those customers up, up, as I say, up the lead table.
But 2 to 5 remain obviously an important component of where we are.
Okay.
Just to add to that, typically Dan, they're obviously more mature relationships and they're kind of in that more mature relationship phase. So you probably wouldn't expect to see quite the levels of growth. We've been we've done well, as you said, with them accelerating over time. But as Steve said as well, we want to see more bonds in our organization. So that's what we're looking for.
And then and maybe just maybe just a few more quick ones. Just on the backlog burn, it looked like it was reasonably stable. I think it was down maybe 10 bps, I think if I look at the model right now on the fly. But how do we think about that? Is this the right zip code, do you think, from here given the backlog and
how things are progressing? Yes.
I don't I think it's one we constantly look at. And to the extent that we win more biotech and small pharma business, Dan, we have the opportunity typically to increase the burn. So that's a the biotech business is a tailwind from a backlog burn point of view, less so with large pharma and less so with the sort of mid pharma. So that and that remains the bulk of our backlog and the bulk of our wins still. So I would anticipate that we'll probably continue at around about the level we're at 8.7%, I think, was the percentage this quarter.
I don't we're trying to push that up. I'd like to think we could push it up over the next 12 months or so, but with the proportion of oncology business we're getting, that is such an important part or such a large part of the landscape at the moment. And that's always a headwind for us. So there's puts and calls on this. I would say we'll be looking to maintain.
Maybe there's opportunity to slightly increase. But I'd say at this stage, I wouldn't expect too much of an increase in the burn rate.
Terrific. Thanks a lot.
Okay. Thank you. And your next question comes from the line of Jack Meehan. Your line is now open. Please go ahead.
Hi, good morning. This is Andrew Wald on for Jack. Just looking at the quarter, how would your growth have compared under the old accounting standard? And were there any notable changes from reimbursed expenses?
Hi, Andrew. I think as we mentioned in the past, there's only one type of revenue, Andrew, and that's the 606 revenue reported, and that's why we talk about it year over year in percentage terms. So I don't think it's useful trying to parse out the revenue into different elements. We have to look at our projects in totality and work our percentage completions on that basis. So we're happy with the progress we've made.
As we've said, 8.5% year over year. And I think that's the number we should probably stick to and think about as we think about revenue growth.
Okay, understood. And on the deal environment, in what areas are you looking to add additional assets for the site network?
I mean, we're looking to round out. I mean, obviously, the Symphony acquisition moves us more towards patients, which has been a very specific and very considered move. We do believe the virtual trial environment is going to be important going forward. So we want to be able to position ourselves well to not just follow and take advantage of that, but to actually get ahead and innovate in that area. So as we look at M and A, we'll continue to look at organizations that facilitate the connection with patients.
Are continuing to look at how we develop our data resources, particularly in partnership with the various groups we've talked about in the past. That's certainly an area. But around recruitment, directing directly to patients, there's opportunities there, I think, to perhaps acquire. But it will be around most of it, I'm sorry, will be around our patient site and data strategy. That's what we've done certainly this year with the acquisitions we've made of MediNova, the lab was a little bit out of that.
But the PMG and the MediNova and now Symphony are very much in line with our patients under. And there are organizations around that that we'll continue to look at in order to facilitate, particularly that patient connection going forward.
Thank you.
Thank you. And your next question comes from the line of Sandy Draper. Your line is now open. Please go ahead.
Thanks very much. And a lot of my questions have been asked and answered. So maybe just a quick one, I missed it Brendan. The constant dollar organic growth number, I got the constant dollar, but I missed the constant dollar organic.
Hey, Sandy. The constant dollar organic in the quarter was 8.4%. Year to date constant CDO, same basis was 9.4%.
Okay, great. Thanks. And then maybe for Steve, a follow-up to one of the earlier questions about the broader dynamics in the market. Just more specifically, have you heard any feedback from customers and their discussions around the DC issues around drug price controls, etcetera. There's certainly some uncertainty there.
If I look back to 2016, there was some noise around the election that caused some people to pause. I'm just curious if customers are bringing that up or if you have that and hear that out there in the market, people are saying, hey, if drug price controls come in, we have to sort of rethink how we do business. I'm just curious any thoughts on that. Thanks.
Yes. Sandy, we don't get much of that feedback from customers, to be honest. It's not to say that they don't have a wish to do things more efficiently and more cost effectively. That's certainly the case. But it's not really on the basis of it, not expressed to us on the basis of drug pricing.
I know it's a topic of conversation within the pharma industry, a constant topic of conversation of how that can potentially evolve going forward. But it really doesn't they don't say it to us, at least not to me. So from my n equals 1 point of view, sorry, I can't give you much joy there or at least much information there.
Okay. No, that's helpful. Thanks.
Thank you. And your next question comes from the line of Michael Pollard. Your line is now open.
Hey, good morning. I was going to ask for more detail on where we stand in the patient engagement site network evolution. But Steve, I think you've addressed a lot of that. So I will shift gears to a couple others that I had. So one for Brendan, we infrequently talk about debt with Icahn because you have a net cash position and generate a lot of cash.
The debt you do have is due December of next year. A note, I'm curious what opportunities you see. Rates have obviously continued to grind lower for the most part. Should we consider that refinance as an opportunity for accretion, roll it over, pay it down, pay some of it down? Any initial thoughts would be useful.
I think, Mike, that we'll certainly be looking to at least roll over. So we had a good experience in the as you know, it's a private placement last time out and it's a market we're well familiar with. So we'll certainly roll it over. We haven't, I suppose, completed our conversations around whether we extend or decrease. I think at the very least, we'll keep it at the similar levels and look opportunistically again with what we could do with those dollars as we go into I suppose really it's as you say quite rightly it's the end of 2020.
So it's really more with Tom conversational what we might do with it in early late 2020, early 2021. So rollover, good PPE market out there, good interest rates at the moment. So we're pretty happy that we'll do at least that and then we'll explore as well as further opportunities as we go through 2020 as to whether we extend that position or not.
Maybe a follow-up also for you Brendan. So you've been asked and answered the question on DSO many times and I think response has been consistent and makes a lot of sense. You are presenting a non GAAP DSO now. Can you remind us why it's a non GAAP DSO? What are we missing?
What are the pieces that we can dig up every quarter to align our calculations, which we were doing, say, last year and the years previous to the new calculation?
Yes, sure, Mike. I mean, the reasons we're doing it that way is purely because part of our direct cost base now is something that previously would have been included in getting to our net revenue position, which is obviously investigator accruals. But investigators are an element of our direct costs now. And as a result, they'll go into a DSO calculation and are kept out separately on the balance sheet. So that's why it is different.
That's now sitting in a different line in the balance sheet. So it doesn't impact and doesn't decrease our DSO in the same way we would have done in the calculation previously. I think that's appropriate from an accounting perspective, but obviously it does have this impact. We're showing the DSO on a like for like basis to give people more historical comparison of where we were in the past and where we are now. We're going to continue to work on it.
But I think working from a calculation of the balance sheet now that would give you a higher number of days is equally valid. I think what we're focused on is making sure that the trajectory of where both of those numbers are going continues to be in the right direction. So we're very focused on making sure that if we bring a non GAAP DSO down by one day, the GAAP number is down by one day as well. So we're very focused on actually making sure that we're moving in the right direction regardless what the number is. But the number right where we quoted at the moment is very comparable to what we would have done in the past to give people some context given that it changed.
Appreciate it. Thank you.
Thank you. And your next question comes from the line of David Windley. Your line is now open. Please go ahead.
Hi, good morning. Good afternoon. Thanks for taking my question. I'm catching up. I'm reading notes.
I don't think this question has been asked. Your gross margin has been under some pressure for a little while and ticked up sequentially in the 3rd quarter, still down year over year, but maybe at a slower rate. Wondered is that just a tremble of the needle or is that actually a signal that some pressures have abated and maybe gross margin can stabilize or even turn higher?
David, it's Steve here. Yes, I think from our point of view, gross margin has been under a little bit of pressure. And as I think I said in my prepared remarks, we recruited fairly actively, particularly in the second quarter, course, 12 months or so. And that had a bit of an impact on our gross margin. I we attenuated or mitigated a little bit the hiring rate in the Q3 and very actively look hard at that.
And that was what led to the uptick, I think, by 20 bps in our Q3 margin. I would expect our gross margin to remain at around that level over the next sort of in the immediate future. We continue to see some challenges there as we've recorded our book to bill at 1.3 for the last, I think, 3 or 4 quarters. And so we've got work to do and we need to recruit people to do that. And we want to make sure we do a really good job because a lot of this work that we're doing, and doing it well brings us repeat business, of course, more even more than that brings us the opportunity to form strategic alliances and partnerships with these customers.
So it's important, obviously, that we do trite statement. So but I do think, as I say, I think we've said publicly for quite a while now, the gross margin is about where it's going to be. It may go up or down a little bit, 10, 20 bps on a quarter to quarter basis, but I don't see much long term progress in terms of that going back to 30 plus percent. I think that will be a challenge. Where we're seeing an opportunity to improve our overall operating income, of course, is we'll continue to leverage the SG and A in our Global Business Services Group and we're able to do that.
This quarter we see some continued opportunity there in the medium to longer term and we certainly intend keep pushing down that road whether it be continued offshoring, robotics, process reengineering, all those good things we talked about quite extensively in the past.
And that's I appreciate that, Steve. And you kind of stole the thunder on my next question, which was to ask how much runway do you think you have? I think ICON is increasingly viewed as one of the best, if not the best, operating manager of its SG and A. You mentioned robotics and offshoring. I hate to ask the trite baseball analogy, but still a lot of innings left in that path?
I haven't got a lot of innings, but I don't think we're at the 8th or 9th. So So I would characterize it to use your baseball team. I'm more a cricketer than a baseball, but I'll use your baseball term for a minute. I would say we're at the top of the 5th or top of the 4th, around that end of the 4th. So I think we're halfway through.
I think there's still plenty of opportunity to continue to do that. And who knows, maybe there's a double header here as well. Another analogy and I think we can as we see further opportunities, we'll keep driving it.
And one last one before I drop. The I think you declined to answer questions about any specific clients. But as you think about maybe by client cohort, bookings and demand in your large pharma, your larger clients versus the smallmid, is it kind of consistently balanced? Or are you seeing some rotation there?
I would characterize that as saying in the large pharma cohort, it's stable. We're seeing plenty of demand or stable demand, I would say. I think you'd have to say the most of the growth has been in the biotech, the smaller customers. But certainly the midsized ones are also we're seeing I think I alluded to some of the partnerships that we brought on in the last 12, 18 months are now starting to really ramp up from a growth point of view. So that growth outside of the top ten is not all biotech customers.
There's a significant number of more midsized, I would say, customers. So I'd say, to paraphrase it all, I'd say large pharma, pretty stable. Biotech certainly moving on the up and midsize sort somewhere in between.
Okay. I appreciate that. Thank you very much.
Great. Thanks, Doug.
Thank you. No further questions have came through, Sir, you may continue.
Okay. Thank you, everyone, for listening in today. We are very pleased that quarter 3 was another strong quarter for IKO and look forward to building on this progress throughout 2019 as we consolidate our position as the CRO partner of choice in drug development. Thank you, everyone.
Thank you. That concludes our conference for today. Thank you all for participating. You may now disconnect.